comparemela.com

Latest Breaking News On - Shuntaro kodama - Page 1 : comparemela.com

LUCA Science Inc : LUCA Science Raises ¥3 86 Billion ($30 3 Million) in Oversubscribed Series B Financing

Series B co-led by Fast Track Initiative, DCI Partners, and 4BIO Capital Proceeds to accelerate development of LUCA's novel Mitochondria Isolation Technology (MIT) platform, IND-enabling activities

United statesUnited kingdomChuo kuCity ofHiroki naritaTomoaki shinoharaTakashi hondoKieran mudryyHiromichi kimuraTai haradaKosuke uedaPhilippe fauchetShuntaro kodamaTsuyoshi sakamotoAndrew kozlovAsahi kasei pharma

4BIO Capital co-leads $30 3 million (¥3 86 Billion) oversubscribed Series B financing in LUCA Science

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Amber fennellPhilippe fauchetShuntaro kodamaKieran mudryyAsahi kasei pharmaAllison connollyRickc tsaiGenevieve wilsonTai haradaNippon venture capital coBio ventures ii lp fundFast track initiativeScience incMitochondrial isolation technologyConsilium strategic communicationsRemiges ventures

Investegate |4Bio Capital Announcements | 4Bio Capital: 4BIO Capital co-leads $30 3 million (¥3 86 Billion) oversubscribed Series B financing in LUCA Science

Investegate announcements from 4Bio Capital, 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science

Amber fennellPhilippe fauchetShuntaro kodamaKieran mudryyAsahi kasei pharmaAllison connollyRickc tsaiGenevieve wilsonTai haradaNippon venture capital coBio ventures ii lp fundFast track initiativeScience incMitochondrial isolation technologyConsilium strategic communicationsRemiges ventures

Mitochondria in focus as 4BIO Capital co-leads financing in LUCA Science

4BIO Capital has co-led Series B financing in LUCA Science Inc., which is developing a novel class of mitochondria biopharmaceutical agents.

United kingdomRickc tsaiTai haradaShuntaro kodamaAsahi kasei pharmaNippon venture capital coScience incFast track initiativeTherapeutics ltdRemiges venturesNissay capital asahi kasei pharmaVenture capitalPhillipe fauchetBiomedical catalyst

vimarsana © 2020. All Rights Reserved.